Future Research Priorities for Morbidity Control of Lymphedema

BACKGROUND: Innovation in the treatment of lower extremity lymphedema has received low priority from the governments and pharmaceutical industry. Advancing lymphedema is irreversible and initiates fibrosis in the dermis, reactive changes in the epidermis and subcutis. Most medical treatments offered...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Indian J Dermatol
Auteurs principaux: Narahari, S R, Aggithaya, Madhur Guruprasad, Moffatt, Christine, Ryan, T J, Keeley, Vaughan, Vijaya, B, Rajendran, P, Karalam, S B, Rajagopala, S, Kumar, N K, Bose, K S, Sushma, K V
Format: Artigo
Langue:Inglês
Publié: Medknow Publications & Media Pvt Ltd 2017
Sujets:
Original Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5286751/
https://ncbi.nlm.nih.gov/pubmed/28216723
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/0019-5154.198039
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires